Download PDF
Semin Respir Crit Care Med 2005; 26(3): 333-341
DOI: 10.1055/s-2005-871992
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Small Cell Lung Cancer

Christos Christodoulou1 , Dimosthenis V. Skarlos1
  • 12nd Oncology Department, “Henry Dunant” Hospital, Athens, Greece
Further Information

Publication History

Publication Date:
29 June 2005 (online)

    Permissions and Reprints

ABSTRACT

Small cell lung cancer (SCLC) is a very chemo- and radiosensitive systemic disease. Combination chemotherapy produces a survival advantage resulting in median survival of 9 to 12 months in extensive disease. Platinum and etoposide in combination with concurrent, early, hyperfractionated chest radiotherapy, in patients with limited disease, produces median survival of 20 months. Prophylactic cranial radiotherapy, in patients with complete response following induction chemotherapy, reduces the incidence of brain metastases and improves survival.

Triplet combinations, dose intensification, and maintenance therapy have not demonstrated meaningful survival improvements.

Recurrent disease can be treated with the same chemotherapy, as in the first line treatment if the progression-free interval exceeds 3 months; otherwise, monotherapy with a novel compound is suggested. Camptothesins (topotecan, irinotecan) appear the most promising new compounds and may become first-line agents for SCLC in the near future.

Molecular advances have provided many new targets for SCLC therapy. Many studies, ongoing or planned, evaluate the effectiveness of new agents developed to attack these targets.

KEYWORDS

Small cell lung cancer - chemotherapy - recurrent small cell lung cancer - chest radiotherapy - prophylactic cranial irradiation

REFERENCES

  • 1 Chrystal K, Cheong K, Harper P. Chemotherapy of small cell lung cancer:state of the art.  Curr Opin Oncol. 2004;  16 136-140
    PubMedGoogle Scholar
  • 2 Hirsch F R, Matthews M J, Aisner S et al.. Histopathologic classification of small cell lung cancer: changing concepts and terminology.  Cancer. 1988;  62 973-977
    PubMedGoogle Scholar
  • 3 Sagman U, Maki E, Evans W K et al.. Small cell carcinoma of the lung: derivation of a prognostic staging system.  J Clin Oncol. 1991;  9 1639-1649
    PubMedGoogle Scholar
  • 4 Osterlind K, Ihde D C, Ettinger D S et al.. Staging and prognostic factors in small-cell carcinoma of the lung.  Cancer Treat Rep. 1983;  67 3-9
    PubMedGoogle Scholar
  • 5 Souhami R L, Bradbury I, Geddes D M et al.. Prognostic significance of laboratory parameters measured at diagnosis in small-cell carcinoma of the lung.  Cancer Res. 1985;  45 2878-2882
    PubMedGoogle Scholar
  • 6 Albain K S, Crowley J J, Lebanc M, Livingston B. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2.580 patients Southwest Oncology Group data base.  J Clin Oncol. 1990;  8 1563-1574
    PubMedGoogle Scholar
  • 7 Christodoulou C, Pavlidis N, Samantas E et al.. Prognostic factors in Greek patients with small cell lung cancer (SCLC): a Hellenic Cooperative Oncology Group Study.  Anticancer Res. 2002;  22 3749-3758
    PubMedGoogle Scholar
  • 8 Sandler A B. Chemotherapy for small cell lung cancer.  Semin Oncol. 2003;  30 9-25
    PubMedGoogle Scholar
  • 9 Turrisi III A T, Kim K, Blum R et al.. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.  N Engl J Med. 1999;  340 265-271
    CrossrefPubMedGoogle Scholar
  • 10 Medical Research Council . Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung.  Br J Cancer. 1979;  40 1
    CrossrefPubMedGoogle Scholar
  • 11 Joss R A, Cavalli F, Goldhirsch A et al.. New drugs in small cell lung cancer.  Cancer Treat Rev. 1986;  13 157-176
    CrossrefPubMedGoogle Scholar
  • 12 Grant S C, Gralla R J, Kris M G et al.. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.  J Clin Oncol. 1992;  10 484-498
    PubMedGoogle Scholar
  • 13 Glisson B S. Recurrent small cell lung cancer: update.  Semin Oncol. 2003;  30 72-78
    CrossrefPubMedGoogle Scholar
  • 14 Lowenbraun S, Bartolucci A, Smalley R V et al.. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma.  Cancer. 1979;  44 4406-4413
    PubMedGoogle Scholar
  • 15 Livingston R B, Moore T N, Heilbrun L et al.. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study.  Ann Intern Med. 1978;  88 194-199
    PubMedGoogle Scholar
  • 16 Jett J R, Everson L, Therneau T M et al.. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer treatment Group.  J Clin Oncol. 1990;  8 33-38
    PubMedGoogle Scholar
  • 17 Messeih A A, Schweitzer J M, Lipton A et al.. Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer.  Cancer Treat Rep. 1987;  71 61-66
    PubMedGoogle Scholar
  • 18 Lowenbraun S, Birch R, Buchanan R et al.. Combination chemotherapy in small cell lung carcinoma: a randomized study of two intensive regimens.  Cancer. 1984;  54 2344-2350
    PubMedGoogle Scholar
  • 19 Fukuoka M, Furuse K, Saijo N et al.. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer.  J Natl Cancer Inst. 1991;  83 855-861
    CrossrefPubMedGoogle Scholar
  • 20 Roth B J, Johnson D H, Einhorn L H et al.. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.  J Clin Oncol. 1992;  10 282-291
    CrossrefPubMedGoogle Scholar
  • 21 Sundstrom S, Bremmes R M, Kaasa S et al.. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small cell lung cancer: results from a randomized phase III trial with 5 years follow up.  J Clin Oncol. 2002;  20 4665-4672
    CrossrefPubMedGoogle Scholar
  • 22 Mascaux C, Paesmans M, Berghamns T et al.. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methology assessment and meta-analysis.  Lung Cancer. 2000;  30 23-36
    CrossrefPubMedGoogle Scholar
  • 23 Pujol J L, Carestia L, Daures J P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.  Br J Cancer. 2000;  83 8-15
    CrossrefPubMedGoogle Scholar
  • 24 Skarlos D V, Samantas E, Kosmidis P et al.. Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Cooperative Oncology Group Study.  Ann Oncol. 1994;  5 601-607
    CrossrefPubMedGoogle Scholar
  • 25 Lassen U, Kristjansen P E, Osterlind K et al.. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer: a randomized trial with 5 years follow up.  Ann Oncol. 1996;  7 365-371
    PubMedGoogle Scholar
  • 26 Noda K, Nishiwak Y, Kawahara M et al.. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer.  N Engl J Med. 2002;  2 85-91
    PubMedGoogle Scholar
  • 27 Loehrer Sr P J, Ansari R, Gonin R et al.. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.  J Clin Oncol. 1995;  13 2594-2599
    PubMedGoogle Scholar
  • 28 Thatcher N, Qian W, Girling D J. Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21) [abstract 2489].  Proc Am Soc Clin Oncol. 2003;  22 619
    PubMedGoogle Scholar
  • 29 Niel H, Herndon J, Miller A et al.. Randomized phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer [abstract].  J Clin Oncol. 2005;  23 3752-3759
    CrossrefPubMedGoogle Scholar
  • 30 Mavroudis D, Papadakis E, Veslemes M et al.. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.  Ann Oncol. 2001;  12 463-470
    CrossrefPubMedGoogle Scholar
  • 31 Reck M, von Pawel J, Macha H N et al.. Randomized phase III trial of paclitaxel, etoposide and carboplatin versus carboplatin, etoposide and vincristine in patients with small-cell lung cancer.  J Natl Cancer Inst. 2003;  95 1118-1127
    PubMedGoogle Scholar
  • 32 Sekine I, Nishiwaki Y, Noda K et al.. Randomized phase II study of cisplatin irinotecan and etoposide combination administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG 9902-DI).  Ann Oncol. 2003;  14 709-714
    CrossrefPubMedGoogle Scholar
  • 33 Briasoulis E, Samantas E, Skarlos D V et al.. Phase I study of etoposide, cisplatin and irrinotecan triplet in patients with advanced stage small cell lung cancer.  Cancer Chemoth and Pharmacol. , In press
    PubMedGoogle Scholar
  • 34 Ihde D C. Chemotherapy of lung cancer.  N Engl J Med. 1992;  327 1434-1441
    CrossrefPubMedGoogle Scholar
  • 35 Beith J M, Clarke S J, Woods R L et al.. Long-term follow-up of a randomized trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung.  Eur J Cancer. 1996;  32A 438-443
    PubMedGoogle Scholar
  • 36 Spiro S G, Souhami R L, Geddes D M et al.. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.  Br J Cancer. 1989;  59 578-583
    CrossrefPubMedGoogle Scholar
  • 37 Jarry O, Fournel P. A randomized trial of 4 versus 8 courses of chemotherapy in small cell lung cancer. IASLC-SCLC, Denver, CO 1994 [abstract]
    Google Scholar
  • 38 Bleehen N M, Girling D J, Machin D et al.. A randomized trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC).II: quality of life. Medical Research Council Lung Cancer Working Party.  Br J Cancer. 1993;  68 1150-1156
    PubMedGoogle Scholar
  • 39 Sculier J P, Berghmans T, Castaigne C et al.. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature.  Lung Cancer. 1998;  19 141-151
    CrossrefPubMedGoogle Scholar
  • 40 Tjan-Heijnen V C, Wagener D J, Postmus P E. An analysis of chemotherapy dose and dose - intensity in small-cell lung cancer: lessons to be drawn.  Ann Oncol. 2002;  13 1519-1530
    CrossrefPubMedGoogle Scholar
  • 41 Postmus P E, Scagliotti G, Groen H J et al.. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.  Eur J Cancer. 1996;  32A 1498-1503
    PubMedGoogle Scholar
  • 42 Skarlos D, Pectasides D, Samantas E et al.. Weekly alternating non-cross resistant chemotherapy for small cell lung cancer with a good prognosis: a Hellenic Cooperative Oncol Group.  Am J Clin Oncol. 1999;  22 87-93
    CrossrefPubMedGoogle Scholar
  • 43 Perry M C, Eaton W L, Propert K J et al.. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.  N Engl J Med. 1987;  316 912-918
    CrossrefPubMedGoogle Scholar
  • 44 Perry M C, Herdon J E, Eaton W L et al.. Thoracic radiation therapy added to chemotherapy modality treatment of limited-stage small-cell lung cancer: an update of cancer and leukemia group B study 8083.  J Clin Oncol. 1998;  16 2466-2467
    PubMedGoogle Scholar
  • 45 Bunn P A, Lichter A S, Makuch R W et al.. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective randomized trial.  Ann Intern Med. 1987;  106 655-662
    PubMedGoogle Scholar
  • 46 Johnson D H, Bass D, Einhon L H et al.. Combination chemotherapy with or without thoracic radiotherapy in limited stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.  J Clin Oncol. 1993;  11 1223-1229
    PubMedGoogle Scholar
  • 47 Perez C A, Einhorn L, Oldham R K et al.. Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report.  J Clin Oncol. 1984;  2 1200-1208
    PubMedGoogle Scholar
  • 48 Osterlind K, Hansen H H, Hansen H S et al.. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer: results of a controlled trial with 5 years follow-up.  Br J Cancer. 1986;  54 7-17
    CrossrefPubMedGoogle Scholar
  • 49 Souhami R L, Geddes D M, Spiro S G et al.. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial.  BMJ. 1984;  288 1643-1646
    CrossrefPubMedGoogle Scholar
  • 50 Pignon J P, Arriagada R, Ihde D C et al.. A meta-analysis of thoracic radiotherapy for small-cell lung cancer.  N Engl J Med. 1992;  327 1618-1624
    CrossrefPubMedGoogle Scholar
  • 51 Warde P, Payne D. Does thoracic irradiation improves survival and local control in limited-stage small cell lung cancer? A meta-analysis [see comments].  J Clin Oncol. 1992;  10 890-895
    CrossrefPubMedGoogle Scholar
  • 52 McCraken J D, Janaki L M, Crowley J J et al.. Concurrent chemotherapy / radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.  J Clin Oncol. 1990;  8 892-898
    PubMedGoogle Scholar
  • 53 Takada M, Fukuoka M, Kawahara M et al.. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.  J Clin Oncol. 2002;  20 3054-3060
    CrossrefPubMedGoogle Scholar
  • 54 Murray N, Coy P, Pater J L et al.. The importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: The NCIC Clinical Trials Group.  J Clin Oncol. 1993;  11 336-344
    PubMedGoogle Scholar
  • 55 Jeremic B, Shibamoto Y, Acimovic L et al.. Initial versus delayed accelerated hyperfractionated radiation and concurrent chemotherapy in limited small cell lung cancer: a randomised study.  J Clin Oncol. 1997;  15 893-900
    PubMedGoogle Scholar
  • 56 Perry M C, Eaton W L, Propert K J et al.. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung.  N Engl J Med. 1987;  316 912-918
    CrossrefPubMedGoogle Scholar
  • 57 Skarlos D V, Samantas E, Briasoulis E et al.. Randomized comparison of early versus late hyperfractionated thoracic irradation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomised phase II study of the Hellenic Cooperative Oncology Group.  Ann Oncol. 2001;  12 1231-1238
    CrossrefPubMedGoogle Scholar
  • 58 Work E, Nielsen O S, Bentzen S M et al.. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.  J Clin Oncol. 1997;  15 3030-3037
    PubMedGoogle Scholar
  • 59 Fried D, Morris D, Hensing T et al.. Timing of thoracic radiation therapy in the combined modality therapy for limited-stage small cell lung cancer: a meta-analysis.  Lung Cancer. 2003;  41(Suppl 2) S23-S28
    PubMedGoogle Scholar
  • 60 Glantz M J, Choy H, Yee L. Prophylactic cranial irradiation in small cell lung cancer: rationale, results and recommendations.  Semin Oncol. 1997;  24 477-483
    PubMedGoogle Scholar
  • 61 Ausperin A, Arriagada R, Pignon J P et al.. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.  N Engl J Med. 1999;  341 476-484
    CrossrefPubMedGoogle Scholar
  • 62 Mangum M D, Greco F A, Hansworth J D et al.. Combined small cell and non-small cell lulng cancer.  J Clin Oncol. 1989;  7 607-612
    PubMedGoogle Scholar
  • 63 Lad T, Piantadosi S, Thomas P et al.. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy.  Chest. 1994;  (Suppl 6) 320S-323S
    PubMedGoogle Scholar
  • 64 Baker R R, Ettinger D S, Ruckdeschel J D et al.. The role of surgery in the management of selected patients with small cell carcinoma of the lung.  J Clin Oncol. 1987;  5 697-702
    PubMedGoogle Scholar
  • 65 Evans W K, Osoba D, Feld R et al.. Etoposide and cisplatin: an effective treatment for relapse in small cell lung cancer.  J Clin Oncol. 1985;  69 479-484
    PubMedGoogle Scholar
  • 66 Moore T D, Korn E L. Phase II trial designs considerations for small-cell lung cancer.  J Natl Cancer Inst. 1992;  84 150-154
    PubMedGoogle Scholar
  • 67 Von Pawel J, Schiller J H, Shepherd F A et al.. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer.  J Clin Oncol. 1999;  17 658-667
    CrossrefPubMedGoogle Scholar
  • 68 Eckardt J, von Pawel J, Hainsworth J et al.. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC): an international phase III study [abstract 2488].  Proc Am Soc Clin Oncol. 2003;  22 619
    PubMedGoogle Scholar
  • 69 Ardizzoni A, Manegold C, Bebruyne C et al.. European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive Small Cell Lung Cancer.  Clin Cancer Res. 2003;  9 143-150
    PubMedGoogle Scholar
  • 70 Christodoulou C, Kalofonos H, Briasoulis E et al.. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).  Cancer Chemoth and Pharmacol. , In press
    PubMedGoogle Scholar
  • 71 Stathopoulos G, Rigatos S, Christodoulou C et al.. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.  Cancer Chemother Pharmacol. 2004;  54 259-264
    PubMedGoogle Scholar
  • 72 Shepherd F A, Amdemichael E, Evans W K et al.. Treatment of small cell lung cancer in the elderly.  J Am Geriatr Soc. 2002;  42 64-70
    PubMedGoogle Scholar
  • 73 Girling D J. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre randomized trial-Medical Research Council Lung Cancer Working Party.  Lancet. 1996;  348 563-566
    CrossrefPubMedGoogle Scholar
  • 74 Gridelli C, De Vivo R, Monfardini S. Management of small-cell lung cancer in the elderly.  Crit Rev Oncol Hematol. 2002;  41 79-88
    PubMedGoogle Scholar
  • 75 Ardizzoni A, Favaretto A, Boni L et al.. Platinum-etoposide chemotherapy in elderly patients with small cell lung cancer: results of a randomized multicenter phase II study assessing attenuated dose or full dose with lenogastim prophylaxis -a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study.  J Clin Oncol. 2005;  23 569-575
    CrossrefPubMedGoogle Scholar
  • 76 Kelly K, Crowley J J, Bunn Jr P A et al.. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group Study.  J Clin Oncol. 1995;  13 2924-2930
    PubMedGoogle Scholar
  • 77 Jett J R, Maksymiuk A W, Su J Q et al.. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer.  J Clin Oncol. 1994;  12 2321-2326
    PubMedGoogle Scholar
  • 78 Shepherd F A, Giaccone G, Seymour O et al.. Prospective randomized double-blind placebo-control trial of Marimastat after response to first-line chemotherapy in patients with small cell lung cancer: a trial of NCI-C-Clinical Trials Group and the EORTC.  J Clin Oncol. 2002;  20 4434-4439
    CrossrefPubMedGoogle Scholar
  • 79 Grant S C, Kris M G, Houghton A N et al.. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin.  Clin Cancer Res. 1999;  5 1319-1323
    PubMedGoogle Scholar
  • 80 Johnson B E, Fisher B, Fisher T et al.. Phase II study of STI571 (GleevecTM) for patients with small cell lung cancer [abstract].  Proc Am Soc Clin Oncol. 2002;  21 293a
    PubMedGoogle Scholar
  • 81 Lee S M, James L E, Mohamed-Ali V et al.. A phase II study of carboplatin / etoposide with thalidomide in small cell lung cancer [abstract 1251].  Proc Am Soc Clin Oncol. 2002;  21 313a
    PubMedGoogle Scholar

Christos ChristodoulouM.D. 

2nd Oncology Department, “Henry Dunant” Hospital

107 Mesogion St., GR-11526, Athens, Greece

Email: hecogiat@otenet.gr